Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07564141 | Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer | PHASE3 | NOT YET_RECRUITING | 688 | — | — | Jul 1, 2026 | Nov 1, 2031 | Jun 3, 2026 | - | — |
| Arm | Type | Description |
|---|---|---|
| Arm 1: Rina-S ± Bevacizumab | EXPERIMENTAL | Participants will receive Rina-S ± bevacizumab once every 3 weeks (Q3W). |
| Arm 2: Investigator Choice of Chemotherapy ± Bevacizumab | ACTIVE_COMPARATOR | Participants will receive carboplatin plus gemcitabine ± bevacizumab, carboplatin plus paclitaxel ± bevacizumab, or carboplatin plus pegylated liposomal doxorubicin (PLD) ± bevacizumab. |
| Name | Type | Description |
|---|---|---|
| Rina-S | BIOLOGICAL | Intravenous (IV) infusion |
| Bevacizumab | DRUG | IV infusion |
| Carboplatin | DRUG | IV infusion |
| Gemcitabine | DRUG | IV infusion |
| Paclitaxel | DRUG | IV infusion |
| PLD | DRUG | IV infusion |
Key Inclusion Criteria: * Participant must have histologically confirmed high-grade serous or endometrioid epithelial ovarian cancer (EOC), including primary peritoneal or fallopian tube cancer. * Participant must have documented recurrence or progression after first-line (1L) platinum-based chemot...